Study on the pathological mechanism of macular edema caused by retinal vein occlusion and related factors affecting treatment prognosis by MLC combined with aqueous humor cytokine detection

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069732

Enrollment

Unknown

Registered

2023-03-24

Start date

2023-04-01

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vein occlusion

Interventions

Anti-VEGF treatment group:Intravitreal injection of Aflibercept

Ozurdex treatment group:Intravitreal injection of Ozurdex

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients aged between 40 and 75 have retinal vein occlusion (RVO) associated with macular edema (macular retinal thickness thresholds of 305µm for male and 290 µm for female) and who need to receive an anti-VEGF drug (Aflibercept) or an intraocular injection of Ozurdex.

Exclusion criteria

Exclusion criteria: (1) Refractive error>3D; (2) Suffering from any other retinitis and choroiditis; (3) Combined with other retinal vascular diseases without macular epiretinal membrane; (4) Combined with other optic nerve diseases (5) History of eye trauma and eye surgery; (6) A history of anti-VEGF therapy, intraocular hormone therapy, and intraocular laser therapy within 3 months, without a history of vitrectomy; (7) Refractive interstitial opacity OCTA image quality is poor (scan quality<6 or significant artifacts)

Design outcomes

Primary

Measure	Time frame
MLC;	—

Secondary

Measure	Time frame
Axial length;BCVA;blood pressure;blood fat;	—

Countries

China

Contacts

Public ContactJun Li

Qingdao Eye Hospital of Shandong First Medical University

doctor_li@126.com+86 15898848551

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026